Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Raising financing through strategic timing

Nature Nanotechnology volume 12, pages 93–98 (2017)Cite this article

Subjects

Strategic timing can be key for nano-drug-delivery ventures to get financing. Timely publications engage potential partners; early broad, blocking, relevant patents demonstrate the potential to appropriate value; and venture formation closer to clinical viability better aligns its timeline with that of venture capitalists.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Emergence of nanobiotechnology firms by subsector.
Figure 2: Strategic timing of BIND Therapeutics.

References

  1. Maine, E., Thomas, V. J., Bliemel, M., Murira, A. & Utterback, J. Nat. Nanotech. 9, 2–5 (2014).

    Article  CAS  Google Scholar 

  2. Maine, E., Thomas, V. J. & Utterback, J. J. Eng. Technol. Manage. 32, 1–25 (2014).

    Article  Google Scholar 

  3. Wagner, V., Dullart, A., Bock, A. & Zweck, A. Nat. Biotechnol. 24, 1211–1217 (2006).

    Article  CAS  Google Scholar 

  4. Patient Capital 3.0: Confronting the Crisis and Achieving the Promise of Venture-Backed Medical Innovation (NVCA, 2013).

  5. Lok, C. Nature 467, 18–21 (2010).

    Article  CAS  Google Scholar 

  6. Kreller, R. Nat. Rev. Drug Discov. 9, 867–882 (2010).

    Article  Google Scholar 

  7. Ford, D. & Nelsen, B. Nat. Biotechnol. 32, 15–23 (2014).

    Article  CAS  Google Scholar 

  8. Von Krogh, G., Battistini, B., Pachidou, F. & Baschera, P. Nat. Biotechnol. 30, 911–915 (2012).

    Article  CAS  Google Scholar 

  9. Pisano, G. Ind. Corp. Change 19, 465–482 (2010).

    Article  Google Scholar 

  10. Dougherty, D. & Dunne, D. Organ. Sci. 22, 1214–1223 (2011).

    Article  Google Scholar 

  11. Schachter, B. Nat. Biotechnol. 30, 944–952 (2012).

    Article  CAS  Google Scholar 

  12. Reif, L. R. A better way to deliver innovation to the world. The Washington Post (22 May 2015).

  13. Christini, A. Nat. Biotechnol. 30, 933–936 (2012).

    Article  CAS  Google Scholar 

  14. Maine, E. R&D Manage. 38, 359–371 (2008).

    Article  Google Scholar 

  15. Maine, E. & Seegopaul. P. Nat. Mater. 15, 487–491 (2016).

    Article  CAS  Google Scholar 

  16. Burgess, P. et al. Nat. Biotechnol. 28, 1267–1270 (2010).

    Article  CAS  Google Scholar 

  17. Kaplan, S. & Murray, F. Res. Sociol. Organ. 29, 107–147 (2010).

    Article  Google Scholar 

  18. Yin, R. K. Case Study Research: Design and Methods 5th edn (Sage Publications, 2014).

    Google Scholar 

  19. Gref, R. et al. Science 263, 1600–1603 (1994).

    Article  CAS  Google Scholar 

  20. Farokhzad, O. C. et al. Proc. Natl Acad. Sci. USA 103, 6315–6320 (2006).

    Article  CAS  Google Scholar 

  21. Langer, R. & Folkman, J. Nature 263, 797–800 (1976).

    Article  CAS  Google Scholar 

  22. Hall, B. & Lerner, J. in Handbook of the Economics of Innovation (eds Hall, B. H. & Rosenberg, N.) Vol. 1, Ch. 14 (Elsevier, 2010).

    Google Scholar 

  23. NVCA 2016 National Venture Capital Association Yearbook (Thomson Reuters, 2016); http://go.nature.com/2i9irza

  24. Thomas, V. J., Bliemel, M., Shippam-Brett, C. & Maine, E. The role of star scientists in university spin-off emergence. In R&D Management Conf. 2016 (2016).

    Google Scholar 

  25. Jones, D. Nat. Rev. Drug Discov. 6, 174–175 (2007).

    Article  Google Scholar 

  26. Langer, R. Challenges and Opportunities at the Confluence of Biotechnology and Nanomaterials (AAAS, 2013); http://go.nature.com/2irWorf

    Google Scholar 

  27. Zurutuza, A. & Marinelli, C. Nat. Nanotech. 9, 730–734 (2014).

    Article  CAS  Google Scholar 

  28. Maine, E. Rev. Nanosci. Nanotechnol. 2, 301–308 (2013).

    Article  Google Scholar 

  29. Maine, E. & Garnsey, E. Res. Pol. 35, 375–393 (2006).

    Article  Google Scholar 

  30. Hrkach, J. et al. Sci. Transl. Med. 4, 128ra39 (2012).

    Article  Google Scholar 

  31. Huggett, B. Nat. Biotechnol. 31, 697–703 (2013).

    Article  CAS  Google Scholar 

  32. Nicholson, S., Danzon, P. & McCullough, J. J. Bus. 78, 1433–1464 (2005).

    Article  Google Scholar 

  33. Ledford H. Nature 533, 304–305 (2016).

    Article  CAS  Google Scholar 

  34. Brickley, P. Pfizer cleared to buy nanotech drug firm BIND therapeutics. Wall Street Journal (27 July 2016).

  35. Hsu, D. & Ziedonis, R. Acad. Manage. Proc. http://doi.org/bhx4gq (2008).

  36. Guzman, J. & Stern, S. Science 347, 606–609 (2015).

    Article  CAS  Google Scholar 

  37. Booth, B. L. Nat. Biotechnol. 34, 25–30 (2016).

    Article  CAS  Google Scholar 

  38. Bubela, T. M. & Caulfield, T. Trends Biotechnol. 28, 447–451 (2010).

    Article  CAS  Google Scholar 

  39. Nelsen, L. L. Nat. Rev. Mol. Cell Biol. 5, 243–247 (2004).

    Article  CAS  Google Scholar 

  40. Chandler, D. L. 3 Questions: Lita Nelsen and the Technology Licensing Office. MIT News (7 November 2014); http://go.nature.com/2j9Pwga

  41. Williams, H. J. Polit. Econ. 121, 1–27 (2013).

    Article  Google Scholar 

  42. Edwards, A., Bountra, C., Kerr, D. & Willson, T. Nat. Chem. Biol. 5, 436–440 (2009).

    Article  CAS  Google Scholar 

  43. Edwards, A. Nature 533, S70 (2016).

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank L. Foster, R. Langer, S. Minick, P. Burgess and O. Farokhzad for time and access provided and the participants of the Academy of Management Conference 2015, the Personalized Medicine Summit 2015, the International Schumpeter Society Conference 2016 and the R&D Management Conference 2016 for their feedback. In addition, the authors are grateful to Mitacs, the Centre for Drug Research and Development Ventures Inc., and the Beedie School of Business (Simon Fraser University) for funding through a Mitacs Elevate post-doctoral fellowship (grants IT02825 & IT02992).

Author information

Authors and Affiliations

  1. Elicia Maine and V. J. Thomas are at the Beedie School of Business, Simon Fraser University, Vancouver V6C 1W6, Canada,

    Elicia Maine & V. J. Thomas

Authors
  1. Elicia Maine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. J. Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elicia Maine.

Supplementary information

Supplementary information

Global Nanobiotechnology Firm Sample (PDF 362 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maine, E., Thomas, V. Raising financing through strategic timing. Nature Nanotech 12, 93–98 (2017). https://doi.org/10.1038/nnano.2017.1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nnano.2017.1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research